VALIANTLAB · Valiant Laboratories Limited · Financials
Volume · Nov 13
318
Avg daily vol (3M)
24.64K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
2.37B
+78%
FY2026
Net Income
-32.68M
-48.5%
FY2026
Operating Cash Flow
-104.32M
-894.4%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 |
|---|---|---|---|---|
| INR | 3.77B | 2.37B | 1.33B | 1.82B |
| INR | 114.94M | 60.4M | 20.93M | 19.66M |
| INR | 37.16M | 19.03M | 1.75M | 778K |
| INR | 249.16M | 7.68M | -15.13M | -7.7M |
| INR | 86.97M | 40.36M | 6.89M | -10.89M |
| INR | 162.19M | -32.68M | -22.01M | 3.2M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2026: 0 in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.